Candel Therapeutics, Inc. CADL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$8.86M-220% | -$29.5M-110% | -$11.27M-5.9% | -$4.8M+78.4% | $7.38M+190% | ||
| $149K-39.2% | $163K-33.5% | $200K0.0% | $200K0.0% | $245K-2.4% | ||
| $1.45M+362% | $1.29M+3.7% | $1.16M-1.8% | $1.05M-43.0% | $314K-69.9% | ||
| —— | —— | -$300K— | —— | —— | ||
| $1.7M+235% | $33K+159% | —— | $1.01M+2,679% | $507K+914% | ||
| -$3.86M-62.9% | $2.29M+321% | —— | —— | -$2.37M-49.5% | ||
| $1.26M+854% | —— | —— | $1.94M+1,465% | -$167K-528% | ||
| -$22K-149% | $44.5K— | $44.5K— | $44.5K— | $44.5K— | ||
| -$108K+20.6% | -$105K+21.6% | -$129K+0.8% | -$139K-10.3% | -$136K-10.6% | ||
| -$18.04M-109% | -$10.57M-81.8% | -$10.24M-55.7% | -$8.89M-43.4% | -$8.62M-2.1% | ||
| $675K+22,400% | $409K+13,533% | $144K— | $31K+417% | $3K-57.1% | ||
| —— | $6.75K— | $6.75K— | $6.75K— | $6.75K— | ||
| -$675K-22,400% | -$409K-13,533% | -$117K— | -$31K-417% | -$3K+57.1% | ||
| $28K-92.7% | —— | —— | $4.65M+34.7% | $384K+106% | ||
| $93.82M+5,117% | $43.9M-52.2% | $0-100% | $17.44M+797% | -$1.87M-49.0% | ||
| $75.1M+816% | $32.92M-61.8% | -$13.72M-180% | $8.52M+300% | -$10.49M-8.1% | ||
| $1.22M+385% | $709K+113% | $127K-69.8% | $192K-61.0% | $252K-54.1% | ||
| —— | —— | —— | —— | —— | ||
| $306K+595% | $263K+406% | $21K-66.1% | $32K-56.2% | $44K-47.0% | ||
| $149K-39.2% | $163K-33.5% | $200K0.0% | $200K0.0% | $245K-2.4% | ||
| -$108K+20.6% | -$105K+21.6% | -$129K+0.8% | -$139K-10.3% | -$136K-10.6% | ||
| $21K+520% | $2K+117% | $40K+767% | -$13K+38.1% | -$5K+64.3% | ||
| $1.26M+854% | —— | —— | $1.94M+1,465% | -$167K-528% | ||
| $39K+14.7% | $35K+16.7% | $34K+13.3% | $35K+20.7% | $34K+13.3% | ||
| $92K+24.3% | $89K+23.6% | $81K+15.7% | $77K+14.9% | $74K+13.8% | ||
| —— | $11.99M— | $11.99M— | $11.99M— | $11.99M— | ||
| —— | -$4.23M-69.3% | -$2.5M0.0% | -$2.5M0.0% | -$2.5M-50.0% | ||
| $39K+144% | $7K— | $112K+3,633% | $0— | $16K— | ||
| $299K+1,296% | —— | —— | —— | -$25K— | ||
| —— | $23.25K— | $23.25K— | $23.25K— | $23.25K— | ||
| -$7.64M+48.6% | —— | -$1.15M-170% | -$5.69M-143% | -$14.88M-212,486% | ||
| -$22K-149% | $44.5K— | $44.5K— | $44.5K— | $44.5K— | ||
| -$108K+20.6% | -$105K+21.6% | -$129K+0.8% | -$139K-10.3% | -$136K-10.6% | ||
| —— | $519.75K— | $519.75K— | $519.75K— | $519.75K— | ||
| -$18.71M-117% | -$10.98M-88.7% | -$10.38M-57.9% | -$8.92M-43.8% | -$8.62M-2.1% | ||
| -$18.71M-117% | -$10.98M-88.7% | -$10.38M-57.9% | -$8.92M-43.8% | -$8.62M-2.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Candel Therapeutics, Inc. generate?
- Candel Therapeutics, Inc. (CADL) generated -$47.7M in operating cash flow over the trailing twelve months.
- What is Candel Therapeutics, Inc.'s free cash flow?
- After $1.3M of capital expenditures, Candel Therapeutics, Inc.'s free cash flow was -$49.0M over the trailing twelve months, down 80.0% year over year.
- Where does Candel Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
